课题基金 / 基金详情

Indiana Alzheimer's Disease Research Center

Indiana Alzheimer's Disease Research Center
印第安纳阿尔茨海默病研究中心
批准号:
10666607
负责人:
ANDREW J SAYKIN
金额:
$298.82万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-01 至 2026-06-30
关键词:
AccelerationAddressAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease related dementiaAnimal ModelAwarenessBiologicalBiological MarkersBiological ModelsBrainCaregiversClinicalClinical TrialsCognitionCollaborationsCommunitiesComplexCreativenessDNA sequencingDataData ScienceData ScientistDementiaDevelopmentDiagnosisDisciplineDiseaseDisparityEarly DiagnosisEarly InterventionEducationEnvironmentEnvironmental Risk FactorEtiologyFamilyFamily memberFosteringFunctional disorderGeneticGoalsGrowthHealthcareHeterogeneityImageImpaired cognitionIndianaIndividualIndustryInformaticsInheritedInstitutionInterdisciplinary StudyInternationalInterventionLeadershipMachine LearningMapsMethodologyMethodsMolecularMolecular GeneticsNatureNerve DegenerationParticipantPathogenesisPathway interactionsPatientsPersonsPhasePhenotypePopulation HeterogeneityPositioning AttributePositron-Emission TomographyPrevalencePreventionProcessProteomicsResearchResearch InfrastructureResearch PersonnelResource DevelopmentResourcesRiskRoleScienceScientific Advances and AccomplishmentsScientistStagingSymptomsSystems BiologyTargeted ResearchTherapeuticThinkingTraining and EducationTranslational ResearchTranslationsUnderrepresented PopulationsUniversitiesacademic programadvanced analyticsbiological heterogeneitybrain healthcaregiver interventionsclinical phenotypecognitive testingcohortcollaborative approachcost effectivedementeddisparity reductiondosageearly detection biomarkerseffective therapyethnoracialimprovedinduced pluripotent stem cellinnovationlifestyle factorsmedical schoolsmedical specialtiesmembermetabolomicsmethod developmentmild cognitive impairmentmultimodal neuroimagingmultiple omicsneuropathologynew therapeutic targetnon-drugnovelnovel diagnosticsnovel strategiespharmacologicpre-clinicalprecision medicinepreventprogramsrecruitsocioeconomic diversitystemsuccesssuccessful interventiontau Proteinstherapeutic developmenttool developmenttraining opportunitytranscriptome sequencingtranslational scientist

项目摘要

项目成果

ANDREW J SAYKIN的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结- IADRC总体
英文摘要
Project Summary – IADRC Overall The Indiana Alzheimer’s Disease Research Center (IADRC) was established in 1991 to bring investigators and institutional resources at the Indiana University School of Medicine (IUSM) together to address the fundamental causes and treatment of Alzheimer’s disease (AD) and related dementias (ADRD). Despite many important gains, the need for targeted research is greater than ever, with an estimated 5.8 million people in the U.S. suffering from AD/ADRD. Unfortunately, we do not yet know how to prevent AD or have an approved disease modifying intervention. Both are critical to stem the growth in dementia prevalence. The overarching goal of the IADRC going forward is to support the goal of the NAPA to prevent and effectively treat AD by 2025, through innovative research on etiology, early detection, and therapeutics. Biomarker studies indicate that processes leading to AD begin at least 20 years prior to dementia, suggesting that successful interventions must be implemented early. This presents a potential opportunity for early intervention, but the field is challenged by critical barriers decreasing the prospects of timely success. The IADRC has identified the barriers as: a) The current understanding of etiology and pathophysiology is fragmented and incomplete; b) Sensitive, specific, and cost-effective methods for early detection are not available; c) Therapeutic development is hampered by the heterogeneity and complexity of ADRD; d) Shortage of data and translational scientists; and, e) Inadequate diversity at all levels. The IADRC specific aims entail innovation to overcome these barriers and accelerate research toward prevention and effective treatment: 1) Support, enhance, and expand innovative research on ADRD targeting causes, diagnosis, treatment, and prevention; 2) Provide critical research resources and infrastructure to support existing studies and enable new innovative research, utilizing a well-characterized longitudinal clinical cohort, with prioritization of diverse populations including underrepresented groups (URG) and those in preclinical and early symptomatic phases, including subjective cognitive decline and mild cognitive impairment, which will help to advance the identification of easily accessible biomarkers for early detection; 3) Identify and prioritize novel therapeutic targets from high-throughput approaches with rapid translation to proof- of-concept studies using genetic and other enrichment strategies for better biological targeting and reduction of phenotypic and biological heterogeneity for more efficient and cost-effective clinical trials; 4) Increase the number of investigators with deep expertise in advanced data sciences to bridge cellular/molecular processes of neurodegeneration and clinical phenotypes, as well as clinical and translational researchers who can move therapeutic approaches from model systems to clinical trials; 5) Provide educational and training opportunities related to dementia for a broad array of learners, with special emphasis on increasing participation from URG in ADRD related research and healthcare specialties. The IADRC is well-positioned to help achieve the NIA/NAPA goals through sustained and impactful contributions towards prevention and treatment of AD/ADRD.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/trc2.12400
发表时间: 2023-04
期刊: ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS
影响因子: 4.8
作者: [Pena-Garcia, Alex, Richards, Ralph, Richards, Mollie, Campbell, Christopher, Mosley, Hank, Asper, Joseph, Eliacin, Johanne, Polsinelli, Angelina, Apostolova, Liana, Hendrie, Hugh, Tackett, Andrew, Elliott, Caprice, Van Heiden, Sarah, Gao, Sujuan, Saykin, Andrew, Wang, Sophia]
通讯作者: Wang, Sophia
DOI: 10.1111/biom.13775
发表时间: 2023-09
期刊: BIOMETRICS
影响因子: 1.9
作者: [Zhao, Yi, Wang, Bingkai, Liu, Chin-Fu, Faria, Andreia, V, Miller, Michael, I, Caffo, Brian S., Luo, Xi]
通讯作者: Luo, Xi
Paravascular fluid dynamics reveal arterial stiffness assessed using dynamic diffusion-weighted imaging.
血管旁流体动力学揭示了使用动态扩散加权成像评估的动脉僵硬度。
DOI: 10.1002/nbm.5048
发表时间: 2024
期刊: NMR in biomedicine
影响因子: 2.9
作者: [Wen,Qiuting, Wright,Adam, Tong,Yunjie, Zhao,Yi, Risacher,ShannonL, Saykin,AndrewJ, Wu,Yu-Chien, Limaye,Kaustubh, Riley,Kalen]
通讯作者: Riley,Kalen
DOI: 10.1097/cce.0000000000000851
发表时间: 2023-01
期刊: Critical care explorations
影响因子: --
作者: []
通讯作者:
6
    Longitudinal Blood-based Transcriptomic Changes in AD: Relation to Clinical and Biomarker Data
    • 批准号:
      10555728
    • 项目类别:
    • 资助金额:
      $78.05万
    • 财政年份:
      2023
    • 负责人:
      ANDREW J SAYKIN
    • 依托单位:
    Administrative Core
    Administrative Core
    Indiana Alzheimer's Disease Research Center
    海外基金